GlassScriptPhysician profile
Mohammed Abusamieh
NPI 1174506109
$7,460.13
in general payments reported to CMS, 2019-2025
38 companies · $1,350 in 2025
The $1,350 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,519 · 2020: $338 · 2021: $874 · 2022: $931 · 2023: $1,287 · 2024: $1,161 · 2025: $1,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,639 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,639.14 |
| Education | $158.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,573.46 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $1,104.55 | 2019-2025 | Tavneos, Enbrel, Krystexxa |
| Janssen Biotech, INC. | $743.66 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $724.30 | 2019-2025 | |
| Pfizer INC. | $544.22 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $322.90 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $286.27 | 2019-2025 | Orencia |
| Ucb, INC. | $279.33 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $263.26 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $150.75 | 2019-2025 | Taltz |
| Horizon Therapeutics Plc | $136.95 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $128.88 | 2022-2025 | Acthar |
| Genentech USA, INC. | $118.74 | 2019-2025 | Actemra, Rituxan, Gazyva |
| La Jolla Pharmaceutical Company | $109.87 | 2019 | |
| Radius Health, INC. | $102.08 | 2019-2025 | Tymlos |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Abusamieh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.